Early infection HIV-1 envelope V1-V2 genotypes do not enhance binding or replication in cells expressing high levels of α4β7 integrin

Journal of Acquired Immune Deficiency Syndromes

Volumn 64, Issue 3, 2013, Pages 249-253

  Etemad, Behzad ^a   Gonzalez, Oscar A ^a   McDonough, Sean ^b   Pena Cruz, Victor ^a   Sagar, Manish ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

gut homing integrin a4b7; gut associated lymphoid tissue; HIV 1 envelope; mucosal transmission; selection at transmission

Indexed keywords

ALPHA4 INTEGRIN; ALPHA4BETA7 INTEGRIN; INTEGRIN; UNCLASSIFIED DRUG; INTEGRIN ALPHA4BETA7; VIRUS ENVELOPE PROTEIN;

ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE LYMPHATIC TISSUE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS RECOMBINANT; VIRUS REPLICATION; AMINO ACID SEQUENCE; BINDING SITE; CELL CULTURE; FEMALE; GENETICS; GLYCOSYLATION; IMMUNOLOGY; LONGITUDINAL STUDY; MALE; METABOLISM; MUCOSAL IMMUNITY; PATHOPHYSIOLOGY; STOMACH MUCOSA;

AMINO ACID SEQUENCE; BINDING SITES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; GASTRIC MUCOSA; GENOTYPE; GLYCOSYLATION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; INTEGRINS; LONGITUDINAL STUDIES; MALE; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

EID: 84886425422     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a06ddd     Document Type: Article

References (26)

1. Mehandru S, Poles MA, Tenner-Racz K, et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med. 2004;200:761-770.
2. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol. 2005;5:783-792.
3. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301-309.
4. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009;106: 20877-20882.
5. Nawaz F, Cicala C, Van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 2011;7:e1001301.
6. Sagar M, Wu X, Lee S, et al. HIV-1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection and these modifications affect antibody neutralization sensitivity. J Virol. 2006;80: 9586-9598.
7. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004;303:2019-2022.
8. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005;79:6528-6531.
9. Sagar M, Laeyendecker O, Lee S, et al. Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis. 2009;199:580-589.
10. Frost SD, Liu Y, Pond SL, et al. Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol. 2005; 79:6523-6527.
11. Gnanakaran S, Bhattacharya T, Daniels M, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011;7:e1002209.
12. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80:11776-11790.
13. Sagar M. HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis. 2010;202(suppl 2):S289-S296.
14. Parrish N, Wilen C, Banks L, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin a4b7. PLoS Pathog. 2012; 8:e1002686.
15. Sagar M, Kirkegaard E, Lavreys L, et al. Diversity in HIV-1 envelope V1-V3 sequences early in infection reflects sequence diversity throughout the HIV-1 genome but does not predict the extent of sequence diversity during chronic infection. AIDS Res Hum Retroviruses. 2006;22:430-437.
16. Chatziandreou N, Arauz Belen A, Freitas I, et al. Sensitivity changes over the course of infection increases the likelihood of resistance against fusion but not CCR5 receptor blockers. AIDS Res Hum Retroviruses. 2012;28:1584-1593.
17. Etemad B, Fellows A, Kwambana B, et al. Human immunodeficiency virus type 1 V1-to-V5 envelope variants from the chronic phase of infection use CCR5 and fuse more efficiently than those from early after infection. J Virol. 2009;83:9694-9708.
18. Dudley DM, Gao Y, Nelson KN, et al. A novel yeast-based recombination method to clone and propagate diverse HIV-1 isolates. Biotechniques. 2009;46:458-467.
19. Marozsan AJ, Arts EJ. Development of a yeast-based recombination cloning/system for the analysis of gene products from diverse human immunodeficiency virus type 1 isolates. J Virol Methods. 2003;111: 111-120.
20. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002;46:1896-1905.
21. Rousseau CM, Nduati RW, Richardson BA, et al. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J Infect Dis. 2004;190:1880-1888.
22. Sagar M, Lavreys L, Baeten JM, et al. Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression. J Virol. 2003;77:12921-12926.
23. Pauls E, Ballana E, Moncunill G, et al. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS. 2009;23:266-268.
24. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-2220.
25. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275-1286.
26. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature. 2012;490: 417-420.